Does the media favor CBIO or BCRX?

In the previous week, Crescent Biopharma had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Crescent Biopharma and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.72 beat Crescent Biopharma's score of 0.55 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBIO or PHVS more profitable?

Pharvaris' return on equity of -61.40% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Pharvaris N/A -61.40% -56.00%

Does the media favor CBIO or PHVS?

In the previous week, Pharvaris had 7 more articles in the media than Crescent Biopharma. MarketBeat recorded 14 mentions for Pharvaris and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Pharvaris' score of 0.21 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is VIR or CBIO more profitable?

Vir Biotechnology's return on equity of -29.99% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Vir Biotechnology N/A -29.99% -23.62% Crescent Biopharma N/A -101.50% -86.86%

Does the media prefer VIR or CBIO?

In the previous week, Vir Biotechnology had 16 more articles in the media than Crescent Biopharma. MarketBeat recorded 23 mentions for Vir Biotechnology and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Vir Biotechnology's score of 0.24 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABSI or CBIO more profitable?

Crescent Biopharma has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% Crescent Biopharma N/A -101.50% -86.86%

Does the media refer more to ABSI or CBIO?

In the previous week, Absci had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 9 mentions for Absci and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Absci's score of 0.42 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBIO or BHVN more profitable?

Crescent Biopharma's return on equity of -101.50% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Biohaven N/A -1,328.94% -138.27%

Does the media refer more to CBIO or BHVN?

In the previous week, Crescent Biopharma had 1 more articles in the media than Biohaven. MarketBeat recorded 7 mentions for Crescent Biopharma and 6 mentions for Biohaven. Crescent Biopharma's average media sentiment score of 0.55 beat Biohaven's score of 0.38 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Crescent Biopharma (CBIO) Competitors

$12.91 -1.55 (-10.72%)

Closing price 04:00 PM Eastern

Extended Trading

$12.91 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

CBIO vs. BCRX, PHVS, VIR, ABSI, and BHVN

Should you buy Crescent Biopharma stock or one of its competitors? Crescent Biopharma's main competitors and comparable companies include BioCryst Pharmaceuticals (BCRX), Pharvaris (PHVS), Vir Biotechnology (VIR), Absci (ABSI), and Biohaven (BHVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

Crescent Biopharma (NASDAQ:CBIO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

In the previous week, Crescent Biopharma had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Crescent Biopharma and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.72 beat Crescent Biopharma's score of 0.55 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Crescent Biopharma has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Crescent Biopharma currently has a consensus target price of $32.40, indicating a potential upside of 124.07%. BioCryst Pharmaceuticals has a consensus target price of $20.50, indicating a potential upside of 145.22%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	49.54	-$153.94M	-$6.72	N/A
BioCryst Pharmaceuticals	$874.84M	2.44	$263.86M	-$1.50	N/A

Summary

BioCryst Pharmaceuticals beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Pharvaris?

Crescent Biopharma (NASDAQ:CBIO) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, Pharvaris had 7 more articles in the media than Crescent Biopharma. MarketBeat recorded 14 mentions for Pharvaris and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Pharvaris' score of 0.21 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Crescent Biopharma has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, meaning that its share price is 346% less volatile than the broader market.

Pharvaris' return on equity of -61.40% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Pharvaris	N/A	-61.40%	-56.00%

Crescent Biopharma presently has a consensus price target of $32.40, suggesting a potential upside of 124.07%. Pharvaris has a consensus price target of $58.60, suggesting a potential upside of 89.71%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Crescent Biopharma is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Crescent Biopharma has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	49.54	-$153.94M	-$6.72	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

75.2% of Crescent Biopharma shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Crescent Biopharma beats Pharvaris on 10 of the 15 factors compared between the two stocks.

How does Crescent Biopharma compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Vir Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Crescent Biopharma has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	27.89	-$437.99M	-$1.86	N/A
Crescent Biopharma	$10.84M	49.54	-$153.94M	-$6.72	N/A

In the previous week, Vir Biotechnology had 16 more articles in the media than Crescent Biopharma. MarketBeat recorded 23 mentions for Vir Biotechnology and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Vir Biotechnology's score of 0.24 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology's return on equity of -29.99% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Crescent Biopharma	N/A	-101.50%	-86.86%

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vir Biotechnology presently has a consensus target price of $21.86, suggesting a potential upside of 93.43%. Crescent Biopharma has a consensus target price of $32.40, suggesting a potential upside of 124.07%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Crescent Biopharma beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Absci?

Absci (NASDAQ:ABSI) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Absci currently has a consensus target price of $13.88, suggesting a potential upside of 43.49%. Crescent Biopharma has a consensus target price of $32.40, suggesting a potential upside of 124.07%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

52.0% of Absci shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Absci had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 9 mentions for Absci and 7 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.55 beat Absci's score of 0.42 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Crescent Biopharma	N/A	-101.50%	-86.86%

Absci has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Absci has higher earnings, but lower revenue than Crescent Biopharma. Absci is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$1.56M	1,063.11	-$115.18M	-$0.80	N/A
Crescent Biopharma	$10.84M	49.54	-$153.94M	-$6.72	N/A

Summary

Crescent Biopharma beats Absci on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Biohaven?

Crescent Biopharma (NASDAQ:CBIO) and Biohaven (NYSE:BHVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Crescent Biopharma's return on equity of -101.50% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Biohaven	N/A	-1,328.94%	-138.27%

Crescent Biopharma has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	49.54	-$153.94M	-$6.72	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Crescent Biopharma has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Crescent Biopharma presently has a consensus target price of $32.40, suggesting a potential upside of 124.07%. Biohaven has a consensus target price of $18.69, suggesting a potential upside of 58.84%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Crescent Biopharma is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

In the previous week, Crescent Biopharma had 1 more articles in the media than Biohaven. MarketBeat recorded 7 mentions for Crescent Biopharma and 6 mentions for Biohaven. Crescent Biopharma's average media sentiment score of 0.55 beat Biohaven's score of 0.38 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Crescent Biopharma beats Biohaven on 10 of the 14 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$537.10M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	9.71	193.11	18.97
Price / Sales	44.23	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.90	16.95	10.71	6.03
Net Income	-$153.94M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-4.86%	-4.83%	-3.18%	-3.04%
1 Month Performance	-33.49%	-12.20%	-6.61%	-5.16%
1 Year Performance	25.95%	8.87%	3.69%	-2.48%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	3.3673 of 5 stars	$12.91 -10.7%	$32.40 +151.0%	+27.4%	$537.10M	$10.84M	N/A	44
BCRX BioCryst Pharmaceuticals	3.2162 of 5 stars	$7.95 -1.9%	$20.50 +157.9%	+15.8%	$2.03B	$940.61M	N/A	435	Positive News
PHVS Pharvaris	3.1252 of 5 stars	$31.12 +2.1%	$58.60 +88.3%	+40.5%	$1.99B	N/A	N/A	148
VIR Vir Biotechnology	2.7181 of 5 stars	$11.60 -1.5%	$21.57 +86.0%	+94.8%	$1.99B	$68.56M	N/A	367
ABSI Absci	2.8483 of 5 stars	$10.27 -10.9%	$13.71 +33.5%	+162.8%	$1.98B	$1.56M	N/A	140	News Coverage Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. BCRX, PHVS, VIR, ABSI, and BHVN

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

Summary

How does Crescent Biopharma compare to Pharvaris?

Summary

How does Crescent Biopharma compare to Vir Biotechnology?

Summary

How does Crescent Biopharma compare to Absci?

Summary

How does Crescent Biopharma compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. BCRX, PHVS, VIR, ABSI, and BHVN

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

Does the media favor CBIO or BCRX?

Is CBIO or BCRX more profitable?

Which has more risk & volatility, CBIO or BCRX?

Do analysts recommend CBIO or BCRX?

Do insiders & institutionals believe in CBIO or BCRX?

Which has better valuation & earnings, CBIO or BCRX?

Summary

How does Crescent Biopharma compare to Pharvaris?

Does the media favor CBIO or PHVS?

Which has more volatility & risk, CBIO or PHVS?

Is CBIO or PHVS more profitable?

Do analysts rate CBIO or PHVS?

Which has preferable earnings & valuation, CBIO or PHVS?

Do insiders & institutionals have more ownership in CBIO or PHVS?

Summary

How does Crescent Biopharma compare to Vir Biotechnology?

Which has more volatility & risk, VIR or CBIO?

Which has stronger earnings & valuation, VIR or CBIO?

Does the media prefer VIR or CBIO?

Is VIR or CBIO more profitable?

Do insiders & institutionals hold more shares of VIR or CBIO?

Do analysts rate VIR or CBIO?

Summary

How does Crescent Biopharma compare to Absci?

Do analysts recommend ABSI or CBIO?

Do insiders & institutionals have more ownership in ABSI or CBIO?

Does the media refer more to ABSI or CBIO?

Is ABSI or CBIO more profitable?

Which has more risk & volatility, ABSI or CBIO?

Which has better valuation & earnings, ABSI or CBIO?

Summary

How does Crescent Biopharma compare to Biohaven?

Is CBIO or BHVN more profitable?

Which has better earnings & valuation, CBIO or BHVN?

Which has more risk & volatility, CBIO or BHVN?

Do analysts prefer CBIO or BHVN?

Does the media refer more to CBIO or BHVN?

Do institutionals and insiders have more ownership in CBIO or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools